Human immunodeficiency virus type 1 genomic RNA (HIV-1 RNA genome)

The Human immunodeficiency virus type 1 genomic RNA is a single-stranded, positive-sense RNA molecule approximately 9.7 kilobases in length that serves as both the genetic material packaged within virions and as the mRNA template for the synthesis of viral proteins[1][2][4][5]. It contains multiple highly structured domains within its 5′-untranslated region (5′-UTR), including the trans-activation response (TAR) element, primer-binding site (PBS), dimerization initiation site (DIS), and the Rev-response element (RRE), which together regulate critical steps in the HIV life cycle such as transcription, reverse transcription, translation, splicing, RNA dimerization, and packaging[1][3][6][7]. The RNA genome also functions as a scaffold for assembly of viral proteins and facilitates immune evasion through mechanisms such as inhibition of protein kinase R (PKR)[3][5]. Its complex secondary and tertiary structures constitute druggable targets for experimental antiviral strategies, though clinically approved drugs primarily target encoded enzymes or proteins rather than the genome RNA itself. Monitoring of HIV-1 RNA in plasma is essential for virological assessment in patients, serving as the primary biomarker for infection progression and therapeutic efficacy[5][6][7].

Other names

HIV-1 RNA genomeHIV-1 genomic RNAHIV-1 RNAHuman immunodeficiency virus type 1 genomic RNA

Inhibition of structured RNA-protein interactions (such as Tat-TAR or Rev-RRE binding), Destabilization of RNA secondary structure, Blockade of RNA dimerization/packaging, Interference with translation initiation or splicing